← Back to Home

Maintaining control of intraocular inflammation after steroid withdrawal: brepocitinib meets endpoints in two Phase 3 trials

In two uveitis trials, about 60% of patients receiving the drug achieved steroid-free disease quiescence at week 48, compared with about 20% in the placebo groups. The findings provide new evidence for reducing steroid dependence, but comparisons with existing treatments and long-term safety remain to be clarified.

By SURL BioNews

For patients with noninfectious uveitis, suppressing intraocular inflammation is only half of treatment; whether the disease remains controlled as steroids are gradually withdrawn also affects vision and daily life. Roivant and Priovant announced on October 21 that oral brepocitinib met the primary and all key secondary endpoints in two Phase 3 trials, providing new clinical evidence for reducing steroid dependence.

Brepocitinib is a small-molecule drug that inhibits both TYK2 and JAK1, suppressing inflammation by interfering with immune signaling. The CLARITY program evaluated noninfectious intermediate, posterior, and panuveitis; the findings cannot be directly extended to all inflammatory eye diseases.

According to a summary by the ophthalmology publication Retinal Physician, CLARITY-1 and CLARITY-2 used identical designs and enrolled a total of 371 patients, randomized one to one to receive brepocitinib 45 mg once daily or placebo during a 48-week double-blind treatment period. Both groups first received oral steroids at 60 mg daily for two weeks, followed by a protocol-defined taper to zero over six weeks. This design allowed the trials to test whether the investigational drug could maintain disease control after steroid withdrawal.

The primary endpoint was time to treatment failure during weeks 6 through 48. The companies reported that median time to treatment failure exceeded 48 weeks in the brepocitinib groups in both trials, compared with approximately 12 weeks in the placebo groups, with statistically significant differences in both trials. A pooled analysis showed that 62% of patients receiving the drug achieved steroid-free disease quiescence in both eyes at week 48, compared with 20% receiving placebo—a difference of 42 percentage points. This means inflammation was controlled at the time of assessment, not that the disease had been cured.

The efficacy signals also extended to ocular imaging and patient-reported outcomes. Among eyes with macular edema at baseline, the pooled analysis showed resolution of edema at week 48 in 42% of those receiving the drug, compared with 4.8% receiving placebo. The companies also reported improvements in key secondary endpoints, including choroidal and retinal vascular leakage and patient-reported visual function. However, the trials compared the drug with placebo, so these findings cannot establish superiority over existing nonsteroidal treatments.

Regarding safety, both the companies and Retinal Physician stated that approximately 3% of participants discontinued treatment because of adverse events, and no new safety signals were observed. However, a company investor presentation separately listed serious adverse event rates of approximately 8% in the drug group and 3% in the placebo group. Because treatment exposure differed between the groups, these percentages alone cannot be used to compare risk directly. These events were also not necessarily caused by the drug; complete data and longer follow-up are still needed to assess the benefits and risks of continued treatment.

Priovant plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration in the first half of 2027, seeking an indication for noninfectious uveitis. The information released so far consists primarily of company summaries of the trial results, and Retinal Physician’s reporting is also based on that announcement. The consistent direction of findings across the two trials strengthens their persuasiveness; the upcoming regulatory review will further examine whether the efficacy can translate into a treatment option suitable for long-term use.

References

  1. Roivant Sciences / GlobeNewswire
  2. Retinal Physician